Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...
Alumis' Phase 3 ONWARD data show envudeucitinib delivers durable scalp clearance and itch relief through 48 weeks in ...
A two-year Japanese real-world study of 66 patients shows the dual IL-17A and IL-17F inhibitor bimekizumab sustained high ...
Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...
Zasocitinib demonstrated superiority over deucravacitinib for the treatment of moderate to severe plaque psoriasis, according ...
These growth companies offer investors the potential for near-term upside from fourth-quarter catalysts and long-term growth ...
Icotrokinra (Icotyde) sustained PASI 90 in at least 72% of plaque psoriasis patients through two years in Phase III ICONIC-LEAD. Read the full results.
New data from an Eli Lilly study found that adults with moderate-to-severe psoriasis and obesity experienced broader immune ...
The study involved 274 adults with moderate-to-severe plaque psoriasis and obesity or overweight. Participants were ...
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its oral psoriasis treatment ICOTYDE (icotrokinra) maintained ...
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results ...
If envudeucitinib gains approval, it will join an increasingly competitive market flanked by drugs like J&J’s Icotyde, Amgen’s Otezla and BMS’ Sotyktu.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results